Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Times of India
The Times of India
Lifestyle
TOI Lifestyle Desk | etimes.in

Phase three clinical trial of India's own dengue vaccine, DengiAll, initiated

The first-ever phase three clinical trial for India's indigenous tetravalent dengue vaccine, DengiALL has been initiated. DengiALL has been developed by Panacea Biotec. Currently, there is no antiviral treatment or licensed vaccine against dengue in India.

The phase three clinical trial will be conducted across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.